Ticho Barry

Ticho Barry, Chief Medical Officer at Stoke Therapeutics (STOK), has demonstrated a pronounced selling bias in recent insider transactions, as reflected in SEC Form 4 filings. Over the course of 33 trades, Barry has sold shares totaling $1,294,886.39, while purchasing shares worth only $2,989.35. This significant disparity underscores a clear preference for divestment over accumulation of STOK stock. Notably, all 17 of Barry’s most recent transactions were sales, with no buys recorded in this period. The selling activity has been concentrated in late 2025 and early 2026, with notable transactions occurring on March 17, 2026 ($117,108.83), March 18, 2026 ($190,831.18), and December 5, 2025 ($62,345.80). Smaller sales, such as those on November 3, 2025 ($29,350) and December 2, 2025 ($22,968.13), further illustrate Barry’s consistent divestment strategy. Additionally, several transactions were marked as "M" (merger or acquisition) or "A" (grant or award), but these did not involve monetary exchanges, indicating they were likely related to equity compensation or corporate actions rather than direct market transactions. Barry’s trading pattern, heavily skewed toward selling, aligns with a broader trend of reducing exposure to STOK shares. While the reasons behind these transactions remain undisclosed, the data highlights a sustained effort to liquidate holdings in the company. This activity provides transparency into Barry’s financial decisions regarding STOK stock, offering stakeholders insight into the executive’s investment behavior.